Merck, Moderna skin cancer vaccine reduces disease’s recurrence, spread in large trial
Merck Moderna vaccine
Covered by 12 sources
- Financial Times·2h agoModerna pins hopes on mRNA ‘game-changer’ for cancer vaccines
Technology behind blockbuster Covid-19 jabs is now yielding promising results in oncology treatment
Read at Financial Times → - Al Jazeera·9h agoModerna, Merck unveil mRNA-based cancer vaccine that cuts spread
Moderna's mRNA vaccine Intismeran shows promise, reducing melanoma recurrence and spread in late-stage trials.
Read at Al Jazeera → - CNBC Top News·9h agoCancer vaccine from Moderna, Merck shows promise in late-stage trial; both stocks soar
The combination regimen significantly extended the time patients lived without their melanoma returning, compared with Keytruda alone.
Read at CNBC Top News → - Global News Health·10h agoModerna’s experimental mRNA cancer treatment progresses, shares spike
Moderna and Merck are developing a treatment using an mRNA-based cancer vaccine designed to be tailored to individual patients based on unique mutations within their tumors.
Read at Global News Health → - Ars Technica·13h agomRNA cancer vaccine succeeded in Phase 3 melanoma trial, Moderna and Merck say
The vaccine reportedly thwarted the cancer's return and spread.
Read at Ars Technica → - Bloomberg Markets·13h agoModerna, Merck Revive mRNA Hopes With Melanoma Success
A personalized vaccine developed by Moderna and Merck reduced the recurrence of melanoma in a large, late-stage trial, raising expectations for treating the deadliest form of skin cancer and showing the promise of the embattled mRNA technology. Madison Muller explains (Source:…
Read at Bloomberg Markets → - NYT Health·14h agoModerna, Merck Say mRNA Vaccine Prevents Melanoma From Returning
Moderna and Merck say the experimental vaccine prevented the return and spread of the cancer in high-risk melanoma patients.
Read at NYT Health → - CBC Health·14h agoMerck and Moderna say mRNA melanoma vaccine hits goals in late-stage trial
Merck and Moderna report that a personalized mRNA vaccine helped prevent skin cancer from returning in high-risk patients. Observers greeted the news with enthusiasm but noted that full data from the ongoing late-stage study has yet to be released.
Read at CBC Health → - Economic Times·15h agoModerna shares soar 135% in a day after cancer vaccine succeeds in late-stage trial
Moderna shares surged after its personalized mRNA cancer vaccine trial showed positive results. The treatment, combined with Keytruda, reduced melanoma recurrence and spread significantly. This marks the first successful late-stage trial for an mRNA cancer vaccine. The findings…
Read at Economic Times →
